Obliterative Bronchiolitis

Transplantation

Volumn 100, Issue 2, 2016, Pages 272-283

  Aguilar, Patrick R ^a   Michelson, Andrew P ^a   Isakow, Warren ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; METHOTREXATE; METHYLPREDNISOLONE; PIRFENIDONE; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ANTIBODY MEDIATED REJECTION; BRONCHIOLITIS OBLITERANS; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS INFECTION; DIFFERENTIAL DIAGNOSIS; ENVIRONMENTAL FACTOR; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACORPOREAL PHOTOPHORESIS; FIBROSING ALVEOLITIS; GASTROESOPHAGEAL REFLUX; GRAFT DYSFUNCTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LEUKAPHERESIS; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG GRAFT REJECTION; LUNG LAVAGE; LUNG TRANSPLANTATION; LYMPH NODE IRRADIATION; META ANALYSIS (TOPIC); NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SURVIVAL TIME; T CELL DEPLETION; THORAX RADIOGRAPHY; TREATMENT DURATION; ADVERSE EFFECTS; ANIMAL; BIOPSY; DISEASE COURSE; IMMUNOLOGY; LUNG; PATHOLOGY; PREDICTIVE VALUE; REOPERATION; SURGERY; TIME FACTOR; TREATMENT OUTCOME;

ANIMALS; BIOPSY; BRONCHIOLITIS OBLITERANS; DISEASE PROGRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; LUNG TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; REOPERATION; RESPIRATORY FUNCTION TESTS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84957637697     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000892     Document Type: Review

References (129)

1. Wright JL, Cagle P, Churg A, et al. Diseases of the small airways. Am Rev Respir Dis. 1992;146:240-262.
2. Hachem RR, Trulock EP. Bonchiolitis obliterans syndrome: pathogenesis and management. Semin Thorac Cardiovasc Surg. 2004;16:350-355.
3. Yen KT, Lee As, Krowka MJ, et al. Pulmonary complications in bone marrow transplantation: a practical approach to diagnosis and treatment. Clin Chest Med. 2004;25:189-201.
4. Epler GR, Colby MD, Thomas V, et al. Bronchiolitis obliterans organizing pneumonia. N Engl J Med. 1985;312:152-158.
5. Barker AF, Bergeron A, Rom WN, et al. Obliterative bronchiolitis. N Engl J Med. 2014;370:1820-1828.
6. O'Koren EG, Hogan BL, GunnMD. Loss of basal cells precedes bronchiolitis obliterans-like pathological changes in a murine model of chlorine gas inhalation. Am J Respir Cell Mol Biol. 2013;49:788-797.
7. Weigt SS, DerHovanessian A, Wallace WD, et al. Bronchiolitis obliterans syndrome: the Achilles' heel of lung transplantation. Semin Respir Crit Care Med. 2013;34:336-351.
8. Pain M, Bermudez O, Lacoste P, et al. Tissue remodelling in chronic bronchial diseases: from the epithelial to mesenchymal phenotype. Eur Respir Rev. 2014;23:118-130.
9. Palmer SM, Flake GP, Kelly FL, et al. Severe airway epithelial injury, aberrant repair and bronchiolitis obliterans develops after diacetyl instillation in rats. PLoS One. 2011;6:e17644.
10. Kreiss K, Gomaa A, Kullmann G, et al. Clinical bronchiolitis obliterans in workers at a microwave-popcorn plant. N Engl J Med. 2002;347: 330-338.
11. Morgan DL, Flake GP, Kirby PJ, et al. Respiratory toxicity of diacetyl in C57BL/6 mice. Toxicol Sci. 2008;103:169-180.
12. Morgan DL, Jokinen MP, Price HC, et al. Bronchial and bronchiolar fibrosis in rats exposed to 2,3-pentanedione vapors: implications for bronchiolitis obliterans in humans. Toxicol Pathol. 2012;40:448-465.
13. Morgan DL, Merrick BA, Gerrish KE, et al. Gene expression in obliterative bronchiolitis-like lesions in 2,3-pentanedione-exposed rats. PLoS One. 2015;10:e0118459.
14. Thompson HG, Mih JD, Krasieva TB, et al. Epithelial-derived TGF-beta2 modulates basal and wound-healing subepithelial matrix homeostasis. Am J Physiol Lung Cell Mol Physiol. 2006;291:L1277-L1285.
15. Gilpin SE, Lung KC, Sato M, et al. Altered progenitor cell and cytokine profiles in bronchiolitis obliterans syndrome. J Heart Lung Transplant. 2012;31:222-228.
16. Lapar DJ, Burdick MD, Emaminia A, et al. Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation: a novel clinical biomarker. Ann Thorac Surg. 2011; 92:470-477.
17. Borthwick LA, Parker SM, Brougham KA, et al. Epithelial to mesenchymal transition (EMT) and airway remodeling after human lung transplantation. Thorax. 2009;64:770-777.
18. Hodge S, Holmes M, Banerjee B, et al. Posttransplant bronchiolitis obliterans syndrome is associated with bronchial epithelial to mesenchymal transition. Am J Transplant. 2009;9:727-733.
19. Liu X. Inflammatory cytokines augments TGF-beta1-induced epithelialmesenchymal transition in A549 cells by up-regulating TbetaR-I. Cell Motil Cytoskeleton. 2008;65:935-944.
20. Borthwick LA, McIlroy EI, Gorowiec MR, et al. Inflammation and epithelial to mesenchymal transition in lung transplant recipients: role in dysregulated epithelial wound repair. Am J Transplant. 2010;10: 498-509.
21. Borthwick LA, Sunny SS, Oliphant V, et al. Pseudomonas aeruginosa accentuates epithelial-to-mesenchymal transition in the airway. Eur Respir J. 2011;37:1237-1247.
22. Higuchi T, Jarmaillo A, Kaleem Z, et al. Different kinetics of obliterative airway disease development in heterotopic murine tracheal allografts induced by cd4+ and cd8+ t cells. Transplantation. 2002;74:646-651.
23. West EE, Lavoie TL, Orens JB, et al. Pluripotent allospecific CD8+ effector t cells traffic to lung in murine obliterative airway disease. Am J Respir Cell Mol Biol. 2006;34:108-118.
24. Wu Q, Gupta PK, Suzuki H, et al. CD4 T cells but not TH17 cells are required for mouse lung transplant obliterative bronchiolitis. Am J Transplant. 2015;15:1793-1804.
25. Nakagiri T, Warneke G, Avsar M, et al. Lung function early after lung transplantation is correlated with the frequency of regulatory t cells. Surg Today. 2012;42:250-258.
26. Neujahr DC, Larsen CP. Regulatory T cells in lung transplantation-an emerging concept. Semin Immunopathol. 2011;33:117-127.
27. Smith MA, Sundaresan S, Mohanakumar T, et al. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. J Thoracic Cardiovasc Surg. 1998;116:812-820.
28. Chalermskulrat W, Neuringer IP, Schmitz JL, et al. Human leukocyte antigen mismatches predispose to the severity of bronchiolitis obliterans syndrome after lung transplantation. Chest. 2003;123:1825-1831.
29. Girnita AL, Duquesnoy R, Yousem SA, et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant. 2005;5:131-138.
30. Palmer SM, Davis RD, Hadjiliadis D, et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation. 2002;74:799-804.
31. Finlen Copeland CA, Snyder LD, Zaas DW, et al. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients. Am J Respir Crit Care Med. 2010;182:784-789.
32. Hachem RR, Yusen RD, Meyers BF, et al. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant. 2010;29:973-980.
33. Witt CA, Gaut JP, Yusen RD, et al. Acute antibody-mediated rejection after lung transplantation. J Heart Lung Transplant. 2013;32:1034-1040.
34. Goers TA, Ramachandran S, Aloush A, et al. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol. 2008;180:4487-4494.
35. Salini D, Weber J, Ramachandran S, et al. Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J Heart Lung Transplant. 2011;30: 624-631.
36. Triveedhi V, Gautam B, Sarma NJ, et al. Pre-transplant antibodies to K1 tubulin and collagen-V in lung transplantation: clinical correlations. J Heart Lung Transplant. 2013;32:807-814.
37. Devakonda A, Raoof S, Sung A, et al. Bronchiolar disorders: a clinicalradiological diagnostic algorithm. Chest. 2010;137:938-951.
38. Lynch JP, Weigt SS, DerHovanessian A, et al. Obliterative (constrictive) bronchiolitis. Semin Respir Crit Care Med. 2012;33:509-532.
39. Turton CW, Williams G, Green M. Cryptogenic obliterative bronchiolitis in adults. Thorax. 1981;36:805-810.
40. Couture C, Colby TV. Histopathology of bronchiolar disorders. Semin Respir Crit Care Med. 2003;24:489-10.
41. Cagle PT. Constrictive Bronchiolitis. In Cagle PT, ed. Color Atlas and Text of Pulmonary Pathology. 2nd ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2008:312.
42. Cagle PT. Organizing Pneumonia (Bronchiolitis Obliterans Organizing Pneumonia). In Cagle PT, ed. Color Atlas and Text of Pulmonary Pathology. 2nd ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2008;309.
43. Sugino K, Hebisawa A, Uekusa T, et al. Histopathological bronchial reconstruction of human bronchiolitis obliterans. Pathol Int. 2011;61: 192-201.
44. Colombat M, Holifanjanianina S, Hirschi S, et al. Histologic reconstruction of bronchiolar lesions in lung transplant patients with bronchiolitis obliterans syndrome. Am J Surg Pathol. 2014;38:1157-1158.
45. Verleden SE, Vasilescu DM, Willems S, et al. The site and nature of airway obstruction after lung transplantation. Am J Respir Crit Care Med. 2014;189:292-300.
46. Yusen RD, Edwards LB, Kucheryavaya AY, et al. The registry of the international society for heart and lung transplantation: thirty-first adult lung and heart-lung transplant report-2014; focus theme: retransplantation. J Heart Lung Transplant. 2014;33:1009-1024.
47. Meyer KC, Raghu G, Verleden GM, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J. 2014;44:1479-1503.
48. Burke CM, Theodore J, Dawkins KD, et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest. 1984;86:824-829.
49. Cooper JD, Billingham M, Egan T, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant. 1993;12:713-716.
50. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002;21:297-310.
51. Kastelijn EA, van Moorsel CH, Ruven HJ, et al. Genetic polymorphisms and bronchiolitis obliterans syndrome after lung transplantation: promising results and recommendations for the future. Transplantation. 2012; 93:127-135.
52. Neurohr C, Huppmann P, Samweber B, et al. Prognostic value of bronchoalveolar lavage neutrophilia in stable lung transplant recipients. J Heart Lung Transplant. 2009;28:468-474.
53. Ohshimo S, Bonella F, Sommerwerck U, et al. Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantation. J Heart Lung Transplant. 2011;30:1374-1380.
54. Siegelman SS, Sinha SBP, Veith FJ. Pulmonary reimplantation response. Ann Surg. 1973;177:30-36.
55. Christie JD, Carby M, Bag R, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2005;24:1454-1459.
56. Daud SA, Yusen RD, Meyers BF, et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2007;175:507-513.
57. Girgis RE, Tu I, Berry GJ, et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant. 1996;15:1200-1208.
58. Heng D, Sharples LD, McNeil K, et al. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant. 1998;17:1255-1263.
59. DavisWA, Finlen Copeland CA, Todd JL, et al. Spirometrically significant acute rejection increases the risk for BOS and death after lung transplantation. Am J Transplant. 2012;12:745-752.
60. Hussain AN, Siddiqui MT, Holmes EW, et al. Analysis of risk factors for the development of bronchiolitis obliterates syndrome. Am J Respir Crit Care Med. 1999;159:829-833.
61. Glanville AR, Aboyoun CL, Havryk A, et al. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med. 2008;177:1033-1040.
62. Khalifah AP, Hachem RR, Chakinala MM, et al. Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am J Transplant. 2005;5:2022-2030.
63. Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant. 2009;9:1903-1911.
64. Hartwig MG, Anderson DJ, Onaitis MW, et al. Fundoplication after lung transplantation prevents the allograft dysfunction associated with reflux. Ann Thorac Surg. 2011;92:462-468.
65. Paraskeva M, Bailey M, Levvey BJ, et al. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant. 2011;11:2190-2196.
66. Snyder LD, Finlen Copeland CA, et al. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med. 2010;181:1391-1396.
67. Chmiel C, Speich R, Hofer M, et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis. 2008; 46:831-839.
68. Bhinder S, Chen H, Sato M. Air pollution and the development of posttransplant chronic lung allograft dysfunction. Am J Transplant. 2014;14:2749-2757.
69. Nawrot TS, Vos R, Jacobs L, et al. The impact of traffic air pollution on bronchiolitis obliterans syndrome and mortality after lung transplantation. Thorax. 2011;66:748-754.
70. Gottlieb J, Schulz TF,Welte T, et al. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation. 2009;87:1530-1537.
71. Khalifah AP, Hachem RR, Chakinala MM, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med. 2004;170:181-187.
72. Botha P, Archer L, Anderson RL, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation. 2008;85:771-774.
73. McNeil K, Glanville AR, Wahlers T, et al. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation. 2006;81: 998-1003.
74. Cai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation. 2010;90:1511-1515.
75. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant. 2012;31:1073-1086.
76. Vos R, Vanaudenaerde BM, Ottevaere A, et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer J Heart Lung Transplant. 2010;29:1358-1368.
77. Gottlieb J, Szangolies J, Koehnlein T, et al. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2008;85:36-41.
78. Jain R, Hachem RR, Morrell MR, et al. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant. 2010;29: 531-537.
79. Vos R, Vanaudenaerde BM, Verleden SE, et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J. 2011;37:164-172.
80. Verleden GM, Verleden SE, Vos R, et al. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study. Transpl Int. 2011;24:651-656.
81. Zhou H, Latham CW, Zander DS, et al. Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts. J Heart Lung Transplant. 2005;24:1577-1585.
82. Morrell MR, Despotis GJ, Lublin DM, et al. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant. 2010;29:424-431.
83. Benden C, Spelch R, Hofbauer GF, et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation. 2008;86:1625-1627.
84. Greer M, Dierich M, De Wall C, et al. Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients. Am J Transplant. 2013;13:911-918.
85. McKay C, Knight KA, Wright C. Beyond cancer treatment-a review of total lymphoid irradiation for heart and lung transplant recipients. J Med Rad Sci. 2014;61:202.
86. Fisher AJ, RutherfordRM, Bozzino J, et al. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant. 2005;5:537-543.
87. Kawut SM, Lederer DJ, Keshavjee S, et al. Outcomes after lung retransplantation in the modern era. Am J Respir Crit Care Med. 2008; 177:114-120.
88. Sato M, Waddell TK, Wagnetz U, et al. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung Transplant. 2011;30:735-742.
89. Ofek E, Sato M, Saito T, et al. Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis. Mod Pathol. 2013;26:350-356.
90. Sato M, Hwang DM, Waddell TK, et al. Progression pattern of restrictive allograft syndrome after lung transplantation. J Heart Lung Transplant. 2013;32:23-30.
91. Von der Thusen JH, Hansell DM, et al. Pleuroparenchymal fibroelastosis in patients with pulmonary disease secondary to bone marrow transplantation. Mod Pathol. 2011;24:1633-1639.
92. Nakaseko C, Ozawa S, Sakaida E, et al. Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. Int J Hematol. 2011;93:375-382.
93. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;3541:1813-1826.
94. Chien JW, Duncan S,Williams KM, et al. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16:S106-S114.
95. Fujii N, Nakase K, Asakura S, et al. Bronchiolitis obliterans with allogeneic hematopoietic cell transplantation: a 10-year experience of the Okayama BMT Group. Int J Hematol. 2014;99:644-651.
96. Vieira AG, Funke VAM, Nunes EC, et al. Bronchiolitis obliterans in patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transplant. 2014;49:812-817.
97. Forslöw U, Matson J, Gustafsson T, et al. Donor lymphocyte infusion may reduce the incidence of bronchiolitis obliterans after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:1214-1221.
98. Thomas LHS, Loberiza FR, Klein JP, et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest. 2005;128:153-161.
99. Dudek AZ, Mahaseth H, DeFor TE, et al. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant. 2003;9:657-666.
100. Williams KM, Chien JW, Gladwin MT, et al. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA. 2009;302: 306-314.
101. Filipovich AH, Weisdorf D, Pavletic S, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945-956.
102. Gazourian L, Rogers AJ, Ibanga R, et al. Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Am J Hematol. 2014;89: 404-409.
103. Ringdén O, Remberger M, Ruutu T, et al. Increased risk of chronic graftversus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood. 1999;93:2196-2201.
104. Nakasone H, Kanda J, Yano S, et al. A case-control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation. Transpl Int. 2013;26:631-639.
105. Alam N, Marras TK, Atenafu EG, et al. Allogeneic peripheral blood stem cell transplantation significantly increases risk of chronic graft-versushost disease of lung compared with bone marrow transplantation. Biol Blood Marrow Transplant. 2012;18:1905-1910.
106. Ditschkowski A, Elmaagacli AH, Trenschel R, et al. T-cell depletion prevents from bronchiolitis obliterans and bronchiolitis obliterans with organizing pneumonia after allogeneic hematopoietic stem cell transplantation with related donors. Haematologica. 2007;92:558-561.
107. Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17:1072-1078.
108. Thompson PA, Lim A, Panek-Hudson Y, et al. Screening with spirometry is a useful predictor of later development of noninfectious pulmonary syndromes in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:781-786.
109. Ziakis PD, Zervou FN, Zacharioudakis IM, et al. Graft-versus-hostdisease prophylaxis after transplantation: a network meta-analysis. PLoS One. 2014;9:e114735.
110. Dignan FL, Amrolia P, Clark A, et al. Diagnosis and management of chronic graft-versus-host disease. Br J Haematol. 2012;158:46-61.
111. Wolff D, Gerbitz A, Ayuk F, et al. consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant. 2010;16:1611-1628.
112. HildebrandtGC, Fazekas T, Lawitschka A, et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant. 2011;46: 1283-1295.
113. Bergeron A, Belle A, Chevret S, et al. Combined inhaled steroids and bronchodilatators in obstructive airway disease after allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;39:547-553.
114. Khalid M, Al SA, Saleemi S, et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J. 2005;25:490-493.
115. Lam DCL, Lam B, Wong MKY, et al. Effects of Azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT-a randomized double-blinded placebo-controlled study. Bone Marrow Transplant. 2011;46:1551-1556.
116. Norman BC, Jacobsohn DA, Williams KM, et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant. 2011;46: 1369-1373.
117. Busca A, Locatelli F, Marmont F, et al. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2007;82:45-52.
118. Chiang KY, Abhyankar S, Bridges K, et al. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation. 2002; 73:665-667.
119. Flowers ME, Apperley JF, van Besien K, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008;112:2667-2674.
120. Couriel DR, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006;107:3074-3080.
121. Messina C, Locatelli F, Lanino E, et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol. 2003;122: 118-127.
122. Rubegni P, Cuccia A, Sbano P, et al. Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease. Br J Haematol. 2005;130:271-275.
123. Lucid CE, Savani BN, Engelhardt BG, et al. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT. Bone Marrow Transplant. 2011;46:426-429.
124. Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graftversus-host disease with fibrotic features. Blood. 2009;114:709-718.
125. Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 2007; 40:273-277.
126. Kim SJ, Lee JW, Jung CW, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica. 2010;95:1935-1942.
127. Kulkarni S, Powles R, Sirohi B, et al. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant. 2003; 32:165-170.
128. Vogl UM, Nagayama K, Bojic M, et al. Lung transplantation for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: a single-center experience. Transplantation. 2013; 95:623-628.
129. Soubani AO, Kingah P, Alshabani K, et al. Lung transplantation following hematopoietic stem cell transplantation: report of two cases and systematic review of literature. Clin Transplant. 2014;28:776-782.